- Review
Background: Patients with non-small-cell lung cancer (NSCLC) increasingly receive oral targeted therapies and immune checkpoint inhibitors, creating complex medication-management and toxicity-monitoring needs. Pharmacists may contribute through medication optimization, adherence support, patient education, drug-interaction management and multidisciplinary toxicity prevention. Objectives: The objectives of this study were To systematically map the published evidence describing pharmacist and pharmaceutical-care roles relevant to medication safety, adherence, toxicity management, and treatment continuity in NSCLC. Methods: A scoping review was conducted using PubMed/MEDLINE and Web of Science, supplemented by citation and supplementary searching. The search was limited to English-language publications published between 28 August 2016 and 28 August 2026. After reconciliation, 481 unique records were screened. Eligibility was assessed against a NSCLC-specific population and pharmacy/pharmaceutical-care concept criteria. Evidence was classified as core/direct or contextual/supporting. The selection process was reported according to PRISMA-ScR. Results: Of 481 unique records screened, 444 were excluded at title/abstract screening and 37 reports underwent an eligibility assessment. Twenty-three were excluded at this stage, leaving 14 sources of evidence: 11 core/direct and three contextual/supporting sources. Core evidence covered medication optimization and drug–drug interactions, adherence monitoring, adverse-event/toxicity management, patient education, and pharmacist-led ambulatory or multidisciplinary services. Conclusions: Pharmacists contribute meaningfully to medication safety, adherence, toxicity management, and treatment continuity in NSCLC, but the evidence base remains heterogeneous. Larger prospective studies and economic evaluations are needed.
19 November 2026



![Selected geographical examples of pharmaceutical indication, protocol-based supply, and pharmacist prescribing. Country highlighting is illustrative; regulatory authority may be subnational. England depicts the original PGD-based Pharmacy First pathways; the October 2026 prescribing extension is discussed in Section 3.3 and Table 1 and Table 2. Source: prepared by the authors based on references [4,8,10,11,14,15,16,20,21,22,23,24].](https://mdpi-res.com/pharmacy/pharmacy-14-00172/article_deploy/html/images/pharmacy-14-00172-g001-550.jpg)





